In order to test whether our identified BMPR1A-biased BMP2 expression biomarker was useful across tumour types, we investigated disease free survival in Ovarian, Lung, Pancreatic and Prostate cancers, but found no significant alterations (Figs. S5). This evidence concerns the gene BMP2 and prostate carcinoma.